Video Upload Options

References

1. Beysen D, De Jaegere S, Amor D, Bouchard P, Christin-Maitre S, Fellous M,Touraine P, Grix AW, Hennekam R, Meire F, Oyen N, Wilson LC, Barel D,Clayton-Smith J, de Ravel T, Decock C, Delbeke P, Ensenauer R, Ebinger F,Gillessen-Kaesbach G, Hendriks Y, Kimonis V, Laframboise R, Laissue P, Leppig K, Leroy BP, Miller DT, Mowat D, Neumann L, Plomp A, Van Regemorter N, Wieczorek D, Veitia RA, De Paepe A, De Baere E. Identification of 34 novel and 56 known FOXL2 mutations in patients with Blepharophimosis syndrome. Hum Mutat. 2008Nov;29(11):E205-19. doi: 10.1002/humu.20819.
2. Beysen D, De Paepe A, De Baere E. FOXL2 mutations and genomic rearrangementsin BPES. Hum Mutat. 2009 Feb;30(2):158-69. doi: 10.1002/humu.20807. Review.
3. Beysen D, Raes J, Leroy BP, Lucassen A, Yates JR, Clayton-Smith J, Ilyina H,Brooks SS, Christin-Maitre S, Fellous M, Fryns JP, Kim JR, Lapunzina P, Lemyre E,Meire F, Messiaen LM, Oley C, Splitt M, Thomson J, Van de Peer Y, Veitia RA, DePaepe A, De Baere E. Deletions involving long-range conserved nongenic sequences upstream and downstream of FOXL2 as a novel disease-causing mechanism inblepharophimosis syndrome. Am J Hum Genet. 2005 Aug;77(2):205-18.
4. Caburet S, Georges A, L'Hôte D, Todeschini AL, Benayoun BA, Veitia RA. Thetranscription factor FOXL2: at the crossroads of ovarian physiology andpathology. Mol Cell Endocrinol. 2012 Jun 5;356(1-2):55-64. doi:10.1016/j.mce.2011.06.019.
5. Dipietromaria A, Benayoun BA, Todeschini AL, Rivals I, Bazin C, Veitia RA.Towards a functional classification of pathogenic FOXL2 mutations usingtransactivation reporter systems. Hum Mol Genet. 2009 Sep 1;18(17):3324-33. doi: 10.1093/hmg/ddp273.
6. Kuo FT, Bentsi-Barnes IK, Barlow GM, Pisarska MD. Mutant Forkhead L2 (FOXL2)proteins associated with premature ovarian failure (POF) dimerize with wild-type FOXL2, leading to altered regulation of genes associated with granulosa celldifferentiation. Endocrinology. 2011 Oct;152(10):3917-29. doi:10.1210/en.2010-0989.
7. Laissue P, Lakhal B, Benayoun BA, Dipietromaria A, Braham R, Elghezal H,Philibert P, Saâd A, Sultan C, Fellous M, Veitia RA. Functional evidenceimplicating FOXL2 in non-syndromic premature ovarian failure and in theregulation of the transcription factor OSR2. J Med Genet. 2009 Jul;46(7):455-7.doi: 10.1136/jmg.2008.065086.
8. Moumné L, Batista F, Benayoun BA, Nallathambi J, Fellous M, Sundaresan P,Veitia RA. The mutations and potential targets of the forkhead transcriptionfactor FOXL2. Mol Cell Endocrinol. 2008 Jan 30;282(1-2):2-11.Review.
9. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A,Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, SwenertonKD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A,Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C,Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, AparicioSA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Mutation of FOXL2 ingranulosa-cell tumors of the ovary. N Engl J Med. 2009 Jun 25;360(26):2719-29.doi: 10.1056/NEJMoa0902542.
10. Todeschini AL, Dipietromaria A, L'hôte D, Boucham FZ, Georges AB,Pandaranayaka PJ, Krishnaswamy S, Rivals I, Bazin C, Veitia RA. Mutationalprobing of the forkhead domain of the transcription factor FOXL2 providesinsights into the pathogenicity of naturally occurring mutations. Hum Mol Genet. 2011 Sep 1;20(17):3376-85. doi: 10.1093/hmg/ddr244.